Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - New Zealand
doi 10.2147/dmso.s190356
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus

Cureus
2017English

Type 2 Diabetes and Cardiovascular Risk Factors

Current Medical Research and Opinion
Medicine
2011English

Cardiovascular Risk in Patients With Type 2 Diabetes

CMAJ
Medicine
2005English

Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-Of-The-Art Review

Mayo Clinic Proceedings
Medicine
2018English

Practice of Dapagliflozin Application in Patients With Type 2 Diabetes Mellitus

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY
2015English

Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk

Journal of Managed Care Pharmacy
2007English

Dapagliflozin: A New Adjunct in the Treatment of Type 2 Diabetes Mellitus

International Journal of Basic & Clinical Pharmacology
2014English

Cardiovascular Risk Factors and Mitral Annular Calcification in Type 2 Diabetes

Atherosclerosis
Cardiovascular MedicineCardiology
2013English

Risk Reduction for Type 2 Diabetes in Aboriginal Children in Canada

Paediatrics and Child Health
Child HealthPediatricsPerinatology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy